LLY

934.61

-1.88%↓

JNJ

186.19

+0.07%↑

UNH

324.08

-1.1%↓

NVS

126.35

+0.57%↑

ABT

124.59

+0.18%↑

LLY

934.61

-1.88%↓

JNJ

186.19

+0.07%↑

UNH

324.08

-1.1%↓

NVS

126.35

+0.57%↑

ABT

124.59

+0.18%↑

LLY

934.61

-1.88%↓

JNJ

186.19

+0.07%↑

UNH

324.08

-1.1%↓

NVS

126.35

+0.57%↑

ABT

124.59

+0.18%↑

LLY

934.61

-1.88%↓

JNJ

186.19

+0.07%↑

UNH

324.08

-1.1%↓

NVS

126.35

+0.57%↑

ABT

124.59

+0.18%↑

LLY

934.61

-1.88%↓

JNJ

186.19

+0.07%↑

UNH

324.08

-1.1%↓

NVS

126.35

+0.57%↑

ABT

124.59

+0.18%↑

Search

Simulations Plus Inc

Abierto

SectorSanidad

17.06 -0.23

Resumen

Variación precio

24h

Actual

Mínimo

16.96

Máximo

17.55

Métricas clave

By Trading Economics

Ingresos

-70M

-67M

Ventas

-2.1M

20M

P/B

Media del Sector

48.528

77.256

Rentabilidad por dividendo

0.48

Margen de beneficios

-330.585

Empleados

243

EBITDA

327K

5.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

-5.88% downside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.33%

Próximas Ganancias

1 dic 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-10M

341M

Apertura anterior

17.29

Cierre anterior

17.06

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

165 / 374 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 nov 2025, 23:51 UTC

Ganancias

CoreCivic Cuts Fiscal Year Guidance Amid Efforts to Launch New Detention Facilities

5 nov 2025, 23:10 UTC

Ganancias

DBS Third Quarter Net Dips 2.0%

5 nov 2025, 22:55 UTC

Ganancias

Arm Holdings 2Q Profit Climbs on Record Demand

5 nov 2025, 22:23 UTC

Ganancias

NAB's Annual Profit Falls 2.9% Amid Higher Costs, Credit Impairments -- Update

5 nov 2025, 23:52 UTC

Ganancias

United Overseas Bank 3Q Net Interest Income S$2.265B Vs. $2.46B >U11.SG

5 nov 2025, 23:49 UTC

Ganancias

United Overseas Bank 3Q Total Income S$3.40B Vs. S$3.83B >U11.SG

5 nov 2025, 23:49 UTC

Ganancias

United Overseas Bank 3Q Net S$443M Vs. Net S$1.61B >U11.SG

5 nov 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen, U.S. Tech Rebound -- Market Talk

5 nov 2025, 23:42 UTC

Charlas de Mercado

Gold Edges Lower Amid Reduced Odds of Fed Rate-Cut -- Market Talk

5 nov 2025, 23:12 UTC

Ganancias

Nutrien 3Q Adj EPS 97c >NTR.T

5 nov 2025, 23:11 UTC

Ganancias

Nutrien: Initiating Review of Strategic Alternatives for Phosphate Business >NTR.T

5 nov 2025, 23:10 UTC

Ganancias

Nutrien 3Q Sales $6.01B >NTR.T

5 nov 2025, 23:10 UTC

Charlas de Mercado
Ganancias

AppLovin Says Conversion Rate Is Biggest Growth Lever -- Market Talk

5 nov 2025, 23:10 UTC

Ganancias

Nutrien 3Q EPS 96c >NTR.T

5 nov 2025, 23:04 UTC

Ganancias

Qualcomm Stock Slides After Earnings Beat -- Barrons.com

5 nov 2025, 23:03 UTC

Charlas de Mercado

Macklem: Canada's Regulatory Overlap Turns Off Foreign Investors -- Market Talk

5 nov 2025, 22:55 UTC

Charlas de Mercado

Macklem Says Inflation and Productivity Are Intertwined -- Market Talk

5 nov 2025, 22:55 UTC

Ganancias

AppLovin Reports Strong Earnings. The Stock Is Up. -- Barrons.com

5 nov 2025, 22:51 UTC

Ganancias

DBS 3Q Total Income S$5.93B, Up 3% on Year >D05.SG

5 nov 2025, 22:50 UTC

Ganancias

DBS 3Q Net S$2.95B, Down 2.0% on Year >D05.SG

5 nov 2025, 22:44 UTC

Adquisiciones, fusiones, absorciones

Pfizer Preps Improved Offer in Metsera Bidding War -- Update

5 nov 2025, 22:43 UTC

Charlas de Mercado
Ganancias

NAB's Flat Dividend Disappoints Bears at Jarden -- Market Talk

5 nov 2025, 22:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 nov 2025, 22:36 UTC

Charlas de Mercado

Macklem Warns Structural Adjustment Means Slow Canadian Growth -- Market Talk

5 nov 2025, 22:20 UTC

Charlas de Mercado

Bank of Canada Says Budget Plan Identifies Economy's Biggest Weakness -- Market Talk

5 nov 2025, 22:12 UTC

Adquisiciones, fusiones, absorciones

Pfizer: Will Take Action to Preserve Rights Under Previously-Signed Agreement >PFE

5 nov 2025, 22:11 UTC

Adquisiciones, fusiones, absorciones

Pfizer: Confident in Merits of Claims, Belief Metsera Has Acted in Breach of Contractual Obligations >PFE

5 nov 2025, 22:11 UTC

Adquisiciones, fusiones, absorciones

Pfizer Responds to Delaware Chancery Court Ruling

5 nov 2025, 22:01 UTC

Ganancias

Great-West Lifeco 3Q Net C$1.16B >GWO.T

5 nov 2025, 22:01 UTC

Ganancias

Great-West Lifeco 3Q Adj EPS C$1.33 >GWO.T

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

-5.88% descenso

Estimación a 12 Meses

Media 16 USD  -5.88%

Máximo 16 USD

Mínimo 16 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

165 / 374 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat